Patents Represented by Attorney, Agent or Law Firm Todd M. Crissey
-
Patent number: 7928140Abstract: The present invention comprises a new class of compounds capable of modulating the activity of PI3 kinase and, accordingly, useful for treatment of PI3 kinase mediated diseases, including melanomas, carcinomas and other cancer-related conditions. The compounds have a general Formula I wherein each of A1, A2, A3, A4, X, R1 and R2 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of PI3 kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.Type: GrantFiled: August 1, 2008Date of Patent: April 19, 2011Assignee: Amgen Inc.Inventors: Shon Booker, Noel D'Angelo, Derin C. D'Amico, Tae-Seong Kim, Longbin Liu, Kristin Meagher, Mark H. Norman, Kathleen Panter, Laurie B. Schenkel, Adrian L. Smith, Nuria A. Tamayo, Douglas A. Whittington, Ning Xi, Kevin Yang
-
Patent number: 7820665Abstract: The present invention relates to imidazopyridazine compounds of Formula I, such as representative structure A, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.Type: GrantFiled: December 18, 2008Date of Patent: October 26, 2010Assignee: Amgen Inc.Inventors: Shon Booker, Tae-Seong Kim, Hongyu Liao, Longbin Liu, Mark H. Norman, Emily Anne Peterson, Markian Stec, Nuria A. Tamayo
-
Patent number: 6756388Abstract: The invention is a compound of Formula (I): wherein R is —OH, R1 is —OH, R2 is —H, n is 2 or 3 and X is sulfur, or a pharmaceutically acceptable salt of a compound having Formula (1), or a pharmaceutical composition comprising a compound having Formula (1) or a pharmaceutically acceptable salt thereof, or methods of treating bone loss, breast cancer or prostate cancer comprising administering an effective amount of the compound having Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 1, 1996Date of Patent: June 29, 2004Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Paul Da Silva-Jardine, Eric R. Larson, James R. Hauske, Robert L. Rosati
-
Patent number: 6649657Abstract: Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: GrantFiled: September 26, 2002Date of Patent: November 18, 2003Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Hua Z. Ke, Bruce A. Lefker, Robert L. Rosati, David D. Thompson
-
Patent number: 6632834Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in treating conditions responsive to estrogen by the administration of estrogen agonists/antagonists. Conditions responsive to the compositions and methods include rheumatoid arthritis, colon cancer, tissue wounds, skin wrinkles and cataracts. The compositions are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.Type: GrantFiled: January 11, 2001Date of Patent: October 14, 2003Assignee: Pfizer Inc.Inventors: David D. Thompson, Andrew G. Lee, Wesley W. Day, Robert L. Rosati
-
Patent number: 6624177Abstract: The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula I More particularly, the present invention relates to a method of treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.Type: GrantFiled: March 2, 1999Date of Patent: September 23, 2003Assignee: Warner-Lambert CompanyInventors: Patrick Michael O'Brien, Joseph Armand Picard, Drago Robert Sliskovic, Andrew David White
-
Patent number: 6620806Abstract: The present invention provides methods and kits for improving or maintaining vascular health, including preventing myocardial infarction or stroke; maintaining or improving vascular reactivity; treating acute or chronic renal failure, peripheral arterial occlusive disease, coronary artery disease, or Raynaud's phenomenon; or lowering plasma levels of Lp(a) using an estrogen agonist/antagonist.Type: GrantFiled: October 15, 2001Date of Patent: September 16, 2003Assignee: Pfizer Inc.Inventors: Wesley W. Day, Andrew G. Lee, David D. Thompson
-
Patent number: 6613796Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula IType: GrantFiled: November 15, 2001Date of Patent: September 2, 2003Assignee: Pfizer Inc.Inventors: David B. Maclean, David D. Thompson
-
Patent number: 6531485Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: GrantFiled: December 16, 1999Date of Patent: March 11, 2003Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Paul A. DaSilva-Jardine
-
Patent number: 6512002Abstract: This invention relates to methods and pharmaceutical compositions useful in the treatment of conditions that are responsive to the elevation of testosterone levels in the body and the use of estrogen agonists/antagonists for the manufacture of medicaments for the treatment of conditions that are responsive to the elevation of testosterone levels in the body. The compositions are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. These compositions are effective in treating male subject sexual dysfunction and timidity in female subjects including post-menopausal women and are effective in increasing libido in female subjects including post-menopausal women. In the case of male subject sexual dysfunction, the compositions may also include a compound which is an elevator of cyclic guanosine 3′,5′-monophosphate (cGMP).Type: GrantFiled: January 10, 2001Date of Patent: January 28, 2003Assignee: Pfizer Inc.Inventors: Andrew G. Lee, Wesley W. Day, David D. Thompson
-
Patent number: 6498172Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: GrantFiled: August 20, 1999Date of Patent: December 24, 2002Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Bruce A. Lefker, Robert L. Rosati
-
Patent number: 6495715Abstract: The present invention provides compounds that block calcium channels having the Formula I shown below. The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula I.Type: GrantFiled: January 25, 2001Date of Patent: December 17, 2002Assignee: Warner-Lambert CompanyInventors: Lain-Yen Hu, Michael Francis Rafferty, Todd Robert Ryder
-
Patent number: 6469038Abstract: The present invention provides compounds that block calcium channels having the Formula I shown below. The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, asthma, amyotropic lateral sclerosis, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula I.Type: GrantFiled: September 18, 2000Date of Patent: October 22, 2002Assignee: Warner-Lambert CompanyInventors: Lain-Yen Hu, Michael Francis Rafferty, Todd Robert Ryder, Anthony Denver Sercel, Yuntao Song
-
Patent number: 6458781Abstract: The present invention provides compounds that block calcium channels and have the Formula I: The present invention also provides pharmaceutical compositions containing the compounds of Formula I and methods of using them to treat stroke, cerebral ischemia, head trauma, and epilepsy.Type: GrantFiled: October 25, 1999Date of Patent: October 1, 2002Inventors: David Thomas Connor, Lain-Yen Hu, Thomas Charles Malone, Michael Francis Rafferty, Bruce David Roth, Todd Robert Ryder, Anthony Denver Sercel, Yuntao Song
-
Patent number: 6455572Abstract: This invention relates to compounds that are mammalian metabolites of (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol. The compounds of the invention can be used as standards for analytical assays or as intermediates for the further chemical synthesis or biosynthesis of chemical entities. The invention also relates to pharmaceutical compositions for the treatment of disease and methods of treating disease.Type: GrantFiled: April 4, 2001Date of Patent: September 24, 2002Assignee: Pfizer Inc.Inventors: Wesley W. Day, Kim A. Johnson, Chandra A. Prakash, James F. Eggler
-
Patent number: 6451783Abstract: The present invention provides a method of treating obesity, sexual dysfunction (including erectile dysfunction), diabetes, insulin resistance, hyperinsulinemia, Syndrome X, adrenal dysfunction, hypertension, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia, hypertriglyceridemia, or substance abuse, the method comprising the step of administering to a patent having or at risk of having one of the above-mentioned diseases a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors.Type: GrantFiled: January 16, 2001Date of Patent: September 17, 2002Assignee: Pfizer Inc.Inventors: John R. Hadcock, Andrew G. Swick
-
Patent number: 6441193Abstract: Compounds of this formula are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.Type: GrantFiled: December 17, 1999Date of Patent: August 27, 2002Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Paul A. Dasilva-Jardine, Hua Zhu Ke, Robert L. Rosati
-
Patent number: 6441015Abstract: The present invention relates to tetrazole compounds of Formula I, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, and pharmaceutically acceptable salts of the prodrugs. The invention also relates to compositions comprising the tetrazole compounds and to methods of treating obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, and osteoporosis using the tetrazole compounds.Type: GrantFiled: January 23, 2001Date of Patent: August 27, 2002Assignee: Pfizer Inc.Inventors: Gary E. Aspnes, Yuan-Ching P. Chiang
-
Patent number: 6436977Abstract: Based on lasofoxifene's half-life and potency, the drug may be dosed once per week and achieve a similar effect as if given daily.Type: GrantFiled: September 6, 2000Date of Patent: August 20, 2002Assignee: Pfizer Inc.Inventor: David D. Thompson
-
Patent number: 6423689Abstract: The present invention provides compounds that block calcium channels having the Formula I shown below. The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula I.Type: GrantFiled: December 16, 1998Date of Patent: July 23, 2002Assignees: Warner-Lambert Company, Neurex CorporationInventors: Richard John Booth, Louis Brogley, Wayne Livingston Cody, David Thomas Connor, Harriet Wall Hamilton, John Xiaoqiang He, Lain-Yen Hu, Leonard Joseph Lescosky, Thomas Charles Malone, Laszlo Nadasdi, Michael Francis Rafferty, Bruce David Roth, Diego F. Silva, Yuntao Song, Balazs G. Szoke, Laszlo Urge